Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06441955 · ClinicalTrials.gov registry record · Phase 4
Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
A Phase 4 study of COVID-19, Long Haul, sponsored by Well- Konnect Healthcare Services and Research Firm.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06441955: Recruiting Phase 4 study of COVID-19, Long Haul, sponsored by Well- Konnect Healthcare Services and Research Firm.
NCT06441955 is a Phase 4 study of COVID-19, Long Haul that is actively recruiting participants, run by Well- Konnect Healthcare Services and Research Firm. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06441955, a Phase 4 study of COVID-19, Long Haul, is actively recruiting participants, sponsored by Well- Konnect Healthcare Services and Research Firm.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The symptoms of long COVID can include extreme tiredness (fatigue), shortness of breath, memory and concentration issues (brain fog), heart palpitations, dizziness, joint pain, muscle aches, cough, headaches, anxiety, and depression. It's important to note that there are various other symptoms that individuals can experience after a COVID-19 infection, such as loss of smell, chest pain or tightness, difficulty sleeping (insomnia), pins and needles, depression, anxiety, tinnitus, earaches, nausea, diarrhea, stomach aches, loss of appetite, cough, headaches, sore throat, and changes to the sense of smell or taste. To be included in the study, participants must have had symptoms for more than 4 weeks. The goal of the study is to measure biomarkers, identify new ones through clinical trials, and individualize and optimize treatment plans, which may or may not include COVID-19 post-market antivirals, vaccines, and medical care. It's essential to conduct thorough clinical trials to understand the long-term effects of COVID-19 and to develop personalized treatment plans for individuals experiencing long-haul symptoms.
Primary Outcome
Well-Konnect Biopsychosoical Framework and assessment tool (WKBF tool) compared to the APA biopsychological assessment. Health literacy surveillance care program evaluation tool aims to lay the groundwork for a more inclusive and equitable approach to leveraging genomic data and interventions to improve health outcomes for all individuals.
Conditions Studied
Interventions
- DRUG Ritonavir-Boosted Nirmatrelvir (Paxlovid)
- DIAGNOSTIC_TEST Physiological Evaluation
- BIOLOGICAL Moderna COVID-19 Vaccine
- BEHAVIORAL Biopsychological
- BEHAVIORAL Behavioral (e.g., Psychotherapy, Lifestyle Counseling)
Study Locations (1)
Maryland
- NIH Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 4 |
What NCT06441955 shows while recruiting
NCT06441955 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with COVID-19, Long Haul appearing as the primary indexed condition, and to 5 interventions - of which Ritonavir-Boosted Nirmatrelvir (Paxlovid) is the first listed.
NCT06441955 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06441955 about?
NCT06441955 is a clinical study titled "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.". Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The...
What is the current status of trial NCT06441955?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-03-01. Estimated completion is 2030-09-30.
What conditions does trial NCT06441955 study?
This clinical trial studies the following conditions: COVID-19, Long Haul.
What interventions are being tested in trial NCT06441955?
The interventions under investigation include: Ritonavir-Boosted Nirmatrelvir (Paxlovid) (DRUG), Physiological Evaluation (DIAGNOSTIC_TEST), Moderna COVID-19 Vaccine (BIOLOGICAL), Biopsychological (BEHAVIORAL), Behavioral (e.g., Psychotherapy, Lifestyle Counseling) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06441955?
This trial is sponsored by Well- Konnect Healthcare Services and Research Firm, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06441955 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06441955's enrollment target sits among peer trials
100 770th of 2000 higher than 1,149 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI